v3.26.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 23, 2026
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-40738    
Entity Registrant Name RENOVORX, INC.    
Entity Central Index Key 0001574094    
Entity Tax Identification Number 27-1448452    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 2570 West El Camino Real    
Entity Address, Address Line Two Suite 320    
Entity Address, City or Town Mountain View    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94040    
City Area Code 650    
Local Phone Number 284-4433    
Title of 12(b) Security Common Stock, $0.0001 par value    
Trading Symbol RNXT    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 26.6
Entity Common Stock, Shares Outstanding   45,052,706  
Documents Incorporated by Reference None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 1596    
Auditor Name Frank, Rimerman + Co. LLP    
Auditor Location San Francisco, California    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of RenovoRx, Inc. (the “Company”) as of December 31, 2025 and 2024, and the related statements of operations, convertible preferred stock and stockholders’ equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of RenovoRx, Inc. as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.